Non-Muscle-invasive Bladder Cancer (NMIBC) Recruiting Phase 3 Trials for Epirubicin (DB00445)

Back to Non-Muscle-invasive Bladder Cancer (NMIBC)

Also known as: Non-Muscle- Invasive Bladder Cancer / NMIBC / Non-muscle Invasive Bladder Cancer / Non Muscle-invasive Bladder Cancer / Non-muscle-invasive Bladder Cancer / Non-muscle Invasive Bladder Cancer (NMIBC) / Non Muscle Invasive Bladder Cancer / Nonmuscle Invasive Bladder Cancer / Non-Muscle Invasive Bladder Neoplasms / Carcinoma of urinary bladder, superficial (disorder) / Urothelial carcinoma bladder / Bladder transitional cell carcinoma / Transitional cell carcinoma of bladder (disorder)

Indication	Status	Phase
DBCOND0082324 (Non-Muscle-invasive Bladder Cancer (NMIBC))	Recruiting	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04736394	A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients	Treatment	Epirubicin (DB00445)